ReviewSmall (Weinheim an der Bergstrasse, Germany)2026
Functionalized Coacervates for Cancer Therapy: Advances and Prospects in Phase-Separation-Based Intelligent Drug Delivery.
Review in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Functionalized coacervates, a type of nanomaterial inspired by biomolecular condensation, have emerged as an important research direction in biomedicine, particularly in cancer therapy. These membraneless structures formed by liquid-liquid phase separation (LLPS) self-assembly have high drug-loading capacity, favorable biocompatibility, and tunable responsiveness to tumor microenvironment (TME) cues. This programmability enables targeted delivery and controlled release. This review summarizes the latest progress in the design and therapeutic application of functionalized coacervates in cancer therapy. We first introduce the construction strategies, including basic driving forces, material platforms, and advanced architectures. Then, we explain the mechanisms that enhance therapeutic efficacy and reduce toxicity, including enhanced loading and stability, improved pharmacokinetics and tumor accumulation, and enhanced intracellular delivery that can overcome multidrug resistance (MDR). We also discuss spatiotemporal release triggered by TME cues, such as acidity, redox, or enzymatic activity. Next, we highlight applications in chemotherapy, nucleic acid delivery, cancer immunotherapy, multimodal combination therapy, and emerging directions. Finally, we discuss translational challenges and outline future research directions. We aim to provide a coherent framework for researchers and to facilitate the development and clinical translation of coacervate-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.